valsartan has been researched along with Anemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YY; Hsu, WT; Lee, CM; Wang, SR; Weng, SE; Yang, TY | 1 |
| Adamson, C; Curtain, JP; Desai, AS; Docherty, KF; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Campillejo, RD; de Vinuesa, EG; Gervasini, G; Robles, NR; Valladares, J; Villa, J | 1 |
| Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C | 1 |
| Anand, I; Barlera, S; Carbonieri, E; Cohn, J; Gonzini, L; Latini, R; Maggioni, AP; Opasich, C; Tavazzi, L | 1 |
| Aknay, N; Anand, IS; Chiang, YT; Cohn, JN; Florea, VG; Glazer, RD; Hester, A; Kuskowski, MA; Latini, R; Maggioni, AP; Opasich, C; Rector, TS | 1 |
1 review(s) available for valsartan and Anemia
| Article | Year |
|---|---|
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness | 2014 |
4 trial(s) available for valsartan and Anemia
| Article | Year |
|---|---|
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS).
Topics: Aged; Aged, 80 and over; Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardio-Renal Syndrome; Creatinine; Cystatin C; Drug Combinations; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Male; Retrospective Studies; Valsartan | 2021 |
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice.
Topics: Aged; Anemia; Antihypertensive Agents; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prevalence; Prognosis; Prospective Studies; Registries; Risk; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Morbidity; Multivariate Analysis; Prevalence; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
1 other study(ies) available for valsartan and Anemia
| Article | Year |
|---|---|
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril-valsartan.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |